| Market Cap | 3.25M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.12M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -22.00% |
| Sales | 2.88M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -40.00% |
| Dividend | N/A | Price/Book | 0.47 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | - | Quick Ratio | 3.41 | Shares Outstanding | 10.36M | 52W Low Chg | 10.00% |
| Insider Own | 0.00% | ROA | -33.12% | Shares Float | 2.58M | Beta | 1.10 |
| Inst Own | 1.33% | ROE | -73.37% | Shares Shorted/Prior | 273.81K/526.91K | Price | 0.44 |
| Gross Margin | 76.28% | Profit Margin | -177.91% | Avg. Volume | 221,132 | Target Price | - |
| Oper. Margin | -309.37% | Earnings Date | - | Volume | 120,432 | Change | -3.49% |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
